Director Stock Option Grant at Pasithea Therapeutics Corp.

Alfred J. Novak, a director of Pasithea Therapeutics Corp., was granted 42,913 stock options on October 24, 2025, with an exercise price of $0.715 per share. The options are set to vest fully on the one-year anniversary of the grant date, provided Novak remains a director through that date. Additionally, the options will fully vest upon a Change in Control as defined in the company's 2023 Stock Incentive Plan. The options expire on October 23, 2035. This transaction is part of the company's equity incentive plan aimed at retaining key personnel.